NCT07540754招募中1 期
A Multi-center, Single-dose, Parallel-group, Open-label Study to Evaluate the Pharmacokinetics of HRS9531 Injection in Participants With Mild, Moderate, and Normal Hepatic Function
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- Maximum concentration (Cmax)
研究概览
简要总结
This is a Phase I clinical study to compare the pharmacokinetics (PK) of HRS9531 Injection in participants with mild/moderate hepatic impairment and participants with normal hepatic function, and to evaluate the safety of HRS9531 Injection in these participants.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Participants must fully understand and voluntarily sign a written informed consent form before the trial, demonstrating comprehension of the trial content, procedures, and potential adverse reactions; they must also be willing and able to comply with the protocol requirements to complete the study.
- •Female participants of childbearing potential must have a negative baseline serum pregnancy test, must not be lactating, and must agree to use contraceptive measures and refrain from egg donation from the time of signing the informed consent form until 2 months after the last dose of the study drug; male participants with partners of childbearing potential must agree to use contraceptive measures and refrain from sperm donation from the time of signing the informed consent form until 2 months after the last dose of the study drug.
- •Aged 18 to 65 years (inclusive), both male and female.
- •Male participants weigh no less than 50 kg, and female participants weigh no less than 45 kg. Body mass index (BMI) is within the range of 19.0 to 40.0 kg/m² (inclusive).
排除标准
- •Participation in any clinical trial of a drug or medical device within 3 months prior to dosing, or currently within the follow-up period of a clinical study or within 5 half-lives of the investigational drug (whichever is longer).
- •Allergic constitution, including a history of severe drug allergy or drug anaphylaxis, excluding untreated asymptomatic seasonal allergies or individuals with positive skin tests only.
- •Smokers and drinkers who are unable to abstain during the trial period; positive alcohol screening test.
- •Drug abusers or those with a positive urine drug screening test.
- •Blood loss or blood donation ≥400 mL within 3 months prior to dosing, or blood loss or blood donation ≥ 200 mL within 1 month prior to dosing, or receipt of a blood transfusion within 3 months prior to dosing.
- •Undergone any surgery within 6 months prior to dosing, or planned to undergo surgical procedures during the study period.
- •Suffering from malignant tumors, or having a history of malignant tumors within 5 years prior to screening (excluding non-melanoma skin cancer that has been treated with no signs of recurrence, and resected cervical intraepithelial neoplasia).
- •History of severe hypoglycemia.
- •Previous significant gastric emptying abnormalities or factors affecting gastric emptying (e.g., history of gastric bypass surgery, pyloric stenosis), or severe gastrointestinal diseases (e.g., active peptic ulcer, inflammatory bowel disease, etc.), or have undergone gastrointestinal surgery (excluding surgeries with no significant impact on gastrointestinal motility, such as removal of gastrointestinal polyps, appendectomy, hemorrhoidectomy, etc.).
- •Anyone with factors making them unsuitable to participate in this trial evaluated by the investigator.
结局指标
主要结局
Maximum concentration (Cmax)
时间窗: Post-dose from Day 1 to Day 29.
HRS9531 key PK parameter.
The area under the concentration-time curve to the last measurable concentration (AUClast)
时间窗: Post-dose from Day 1 to Day 29.
HRS9531 key PK parameter.
The area under the concentration-time curve extrapolated to infinity (AUCinf)
时间窗: Post-dose from Day 1 to Day 29.
HRS9531 key PK parameter.
次要结局
- Time to maximum concentration (Tmax)(Post-dose from Day 1 to Day 29.)
- Half-life (t1/2)(Post-dose from Day 1 to Day 29.)
- Apparent clearance (CL/F)(Post-dose from Day 1 to Day 29.)
- Apparent volume of distribution (Vz/F)(Post-dose from Day 1 to Day 29.)
- Adverse events (AEs)(Day 1 to Day 36.)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
1 期
A Study of HRS-1301 Tablets in Healthy Subjects and Those With Impaired Kidney FunctionNCT07322016Shandong Suncadia Medicine Co., Ltd.36
招募中
2 期
Phase II Randomized, Open-label, Multicenter Clinical Study Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of SHR-2173 Injection in Patients With Primary Membranous NephropathyNCT07289763Guangdong Hengrui Pharmaceutical Co., Ltd75
招募中
1 期
A Trial of HRS-6209-205 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-6209 in Combination Therapy in Subjects With HR-Positive/HER2-Negative CancerBreast CancerNCT07358377Atridia Pty Ltd.15
招募中
2 期
A Clinical Study Evaluating the Efficacy and Safety of SHR-1139 Injection in Adult Patients With Ulcerative Pyoderma GangrenosumPyoderma GangrenosumNCT07337564Shandong First Medical University10
招募中
1 期
A Phase Ib Study to Evaluate the Efficacy and Safety of HRS-2129 in Patients With Knee OsteoarthritisNCT07351968Shandong Suncadia Medicine Co., Ltd.200